

## Implantica presents the fourth quarter 2023 on February 16 at 15:00 CET

Implantica AG (publ) invites investors to a presentation of the fourth quarter 2023 at 15:00 CET on February 16. The interim report for the fourth quarter will be published at 8:00 a.m. CET on the same day.

The presentation will be in English via an audiocast with teleconference:

If you wish to participate via webcast, please use the following link:

• http://ir.financialhearings.com/implantica-q4-2023

If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference.

• http://conference.financialhearings.com/teleconference/?id=5002461

Speakers:

- CEO Peter Forsell
- CFO Andreas Öhrnberg
- Chief Corporate Affairs Officer Nicole Pehrsson

## For further information, please contact:

Nicole Pehrsson, Investor Relations Telephone (CH): +41 (0)79 335 09 49 nicole.pehrsson@implantica.com

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, info@fnca.se

The information was sent for publication, through the agency of the contact person set out above, on February 5, 2024 at 09:00 a.m. CET.

## **About Implantica**

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop<sup>™</sup>, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB).

Visit <u>www.implantica.com</u> for further information.